AT1 antagonists: a patent review (2008 – 2012)

Bibliography

• Dasgupta C, Zhang L. Angiotensin II receptors and drug discovery in cardiovascular disease. Drug Discov Today 2011;16:22-34
   PubMed Web of Science ®Google Scholar
• Lang CC, Struthers DA. Targeting the renin–angiotensin–aldosterone system in heart failure. Nat Rev Cardiol 2013;10:125-34
   PubMed Web of Science ®Google Scholar
• Pessôa BS, Van der Lubbe N, Verdonk K, et al. Key developments in renin-angiotensin aldosterone system. Nat Rev Nephrol 2013;9:26-36
   Google Scholar
• Naik P, Murumkar P, Giridhar R, et al. Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists - a perspective. Bioorg Med Chem 2010;18:8418-56
   PubMed Web of Science ®Google Scholar
• Tsukamoto O, Kitakaze M. It is time to reconsider the cardiovascular protection afforded by RAAS blockade-overview of RAAS systems. Cardiovasc Drugs Ther 2013;27:133-8
   Google Scholar
• Akazawa H, Yabumoto C, Yano M, et al. ARB and cardioprotection. Cardiovasc Drugs Ther 2013;27:155-60
   Google Scholar
• Steckelings UM, Paulis L, Unger T, et al. Emerging drugs which target rennin-angiotensin-aldosterone system. Expert Opin Emerg Drugs 2011;16:619-30
   PubMed Web of Science ®Google Scholar
• Castan C, Guimberteau F, Meyrueix R, et al. Multimicroparticulate oral pharmaceutical form with modified release of angiotensin II receptor antagonists. US0311315; 2009
   Google Scholar
• Kordikowski A, Saez Munoz C, Ventosa Rull C, et al. Method for preparing amorphous combinations of Angiotensin II receptor antagonists and diuretics. WO125028; 2009
   Google Scholar
• Ruben Dario Sinisterra M, Robston Augusto Souza DS, Frederic Jean Georges F, et al. Preparation of formulations of Angiotensin II AT1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications. US0091541; 2011
   Google Scholar
• Castan C, Guimberteau F, Meyrueix R, et al. Multimicroparticulate oral pharmaceutical form with modified release of angiotensin II receptor antagonists. US0311315; 2009
   Google Scholar
• Ruben D, Sinistera M, Robson Augusto DS, et al. Preparation of formulations of angiotensin II AT1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications. US08293723; 2012
   Google Scholar
• Allison M, Gatlin MR. Pharmaceutical compositions of an AT1-receptor antagonist and insulin secretion enhancer. US07687528; 2010
   Google Scholar
• Madan S, Rathinasabarthy V, Arora VK. Orally disintegrating compositions comprising antihypertensive agents. WO146551; 2010
   Google Scholar
• Claudel S, Gaudin C. Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment. EP2116239; 2009
   Google Scholar
• Bergmann A. Method for the identification of patients in need of therapy having minor cognitive disorders and the treatment of such patients. US0039343; 2011
   Google Scholar
• Melani F, Giuliani S, Maggi Carlo A. Association of xanthine oxidase inhibitors and Angiotensin II receptor antagonists and use thereof. WO141431; 2011
   Google Scholar
• Pershadsingh HA. Novel PRAP ligands that do not cause fluid retention, edema or congestive heart failure. US0094913; 2012
   Google Scholar
• Bonnichsen R. Cosmetic and pharmaceutical compositions comprising ACE inhibitors and/or angiotensin II receptor antagonists. US0219514; 2012
   Google Scholar
• Jensen BV, Bonnichsen R. Use of ACE inhibitors and/or angiotensin II receptor antagonists for the improving and/or maintaining the skin tone and for the treatment of skin ageing. US0143458; 2009
   Google Scholar
• Staudinger HW, Khanskaya IV, Sadeh J. Methods of treating COPD. MX006089; 2010
   Google Scholar
• Baum T, Daniel H, Showalter H. Compositions and methods for treating inflammation conditions of the bowel. WO017312; 2010
   Google Scholar
• Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit 2005;11:194-205
   Web of Science ®Google Scholar
• Dandona P, Dhindsa S, Ghanim H, et al. Angiotensin II and inflammation:the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hyp 2007;21:20-7
   PubMed Web of Science ®Google Scholar
• Worcel M, Sagbolinski ML. Compositions and methods related to heart failure. US0118294; 2009
   Google Scholar
• Schlinger R, Avramoff A. Process for forming solid oral dosage forms of angiotensin II receptor antagonists. US0278909; 2010
   Google Scholar
• Anderson G, Yusuf S, Hilbrich L. Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors. US 0114046; 2008
   Google Scholar
• Iyer EK, Rasendra JHA-KJ, Jain GK, et al. Cardiovascular combinations using renin-angiotensin inhibitors. WO010008; 2008
   Google Scholar
• Garvey DS, Xiong C, Chia-En L, et al. Organic nitric oxide enhancing salts of angiotensin II antagonists compositions and methods of use. US0215838; 2009
   Google Scholar
• Garvey DS. Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use. US0012057; 2009
   Google Scholar
• Notelovitz M, Bennink HJTC, Boerrigter PJ. Treatment of prevention of unscheduled bleeding in women on progestogen containing medication. US0197843; 2009
   Google Scholar
• Norbert B, Hertzel G, Salim Y. Use of angiotensin II type 1 receptor antagonists for the prevention of stroke, diabetes and/or congestive heart failure. EP2277519; 2011
   Google Scholar
• Wu HH, City X. Lead compound of anti-hypertensive drug and method for screening the same. US0221617; 2009
   Google Scholar
• Mahima P, Sarvesh P. In silico identification of novel lead compounds with AT1 receptor antagonist activity: successful application of chemical database screening protocol. Org Med Chem Lett. 2012.2(1):7
   Google Scholar
• Matsoukas J, Gavras C, Vlachakos D, et al. Compounds. WO016515; 2009
   Google Scholar
• Matsoukas J, Maragoudakis M, Vlachakos D, et al. 1,3,5-substituted imidazoles and their use in the treatment of hypertension and methods for their preparation. MX012755; 2009
   Google Scholar
• Matsoukas J, Gavras C, Vlachakos D, et al. 1,3 and 1,3,5 substituted imidazoles as antihypertensives. US0216854; 2010
   Google Scholar
• Matsoukas J, Maragoudakis M, Vlachakos D. Angiotensin II receptor antagonists based on 4(5) substituted imidazoles and transdermal delivery in the treatment of hypertension and cardiovascular diseases. GR0100312B; 2007
   Google Scholar
• Roumelioti P, Resvani A, Durdagi S, et al. An efficient synthesis of a rationally design 1,5 disubstituted imidazole AT1 angiotensin receptor antagonist: reorientation of imidazole pharmacophore groups in losartan reserves high receptor affinity and confirms docking studies. J Comput Aided Mol Des 2010;24:749-58
   Google Scholar
• Agelis G, Resvani A, Matsoukas A, et al. Towards non-peptide Ang II AT1 receptor antagonists based on urocanic acid: rational design, synthesis and biological evaluation. Aminoacids 2011;40:411-20
   Google Scholar
• Agelis G, Resvani A, Durdagi S, et al. The discovery of new potent non-peptide Angiotensin II AT1 receptor blockers: a concise synthesis, molecular docking studies and biological evaluation of N-substituted 5-butylimidazole derivatives. Eur J Med Chem 2012;55:358-74
   Google Scholar
• Agelis G, Resvani A, Koukoulitsa C, et al. Rational design, efficient syntheses and biological evaluation of N,N'-symmetrically bis-substituted butylimidazole analogs as a new class of potent angiotensin II receptor blockers. Eur J Med Chem 2013;62:352-70
   PubMed Web of Science ®Google Scholar
• Mavromoustakos T, Agelis G, Resvani A, et al. Interactions of the potent synthetic AT1 antagonist analog BV6 with membrane bilayers and mesoporous silicate matrices. Biochim Biophys Acta 2013;1828:1846-55
   Google Scholar
• Brooks C, Cheung M, Goodman K, et al. TRPV4 antagonists. WO174340; 2012
   Google Scholar
• Amjad A, Freehold NJ, Lo MM-C, et al. Angiotensin II receptor antagonists. US0238608; 2012
   Google Scholar
• Amjad A, Freehold NJ, Lo MM-C, et al. Angiotensin II receptor antagonists. WO140111; 2009
   Google Scholar
• Amjad A, Lo MM-C, Franklin CQ, et al. Angiotensin II receptor antagonists. US0201621; 2011
   Google Scholar
• Amjad A, Franklin CQ, Lo MM-C, Whitehead BR. Angiotensin II receptor antagonists. WO094242; 2009
   Google Scholar
• Amjad A, Lo MM-C, Franklin CQ, et al. Angiotensin II receptor antagonists. WO070241; 2009
   Google Scholar
• Almirante N, Ferrario M, Stefanini S, et al. Angiotensin II receptor antagonists. WO150007; 2009
   Google Scholar
• Schiesser CH, Hsin IP, Ziogas J, et al. Novel Biphenyl Sartans. WO134019; 2011
   Google Scholar
• Tan NP, Taylor MK, Bottle SE, et al. Novel paramagnetic AT1 receptor antagonists. Chem Commun 2011;47:12083-5
   Google Scholar
• Min LJ, Mogi M, Shudou M, et al. Peroxisome proliferator-activated receptor-g activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice. Hypertension 2012;59:1079-88
   PubMed Web of Science ®Google Scholar
• Martin MC, Foster MC, Brunner HR, et al. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev 2013;65:809-48
   Google Scholar
• Benson CS, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 2004;43:993-1002
   PubMed Web of Science ®Google Scholar
• Schupp M, Janke J, Clasen R. Angiotensin type 1 receptor blockers induce peroxisome proliferator activated receptor-γ activity. Circulation 2004;109:2054-7
   PubMed Web of Science ®Google Scholar
• Miura T, Higashimurayama S, Tagashira J, et al. Novel 2-pyridone derivative and pharmaceutical product containing same. US0225896; 2012
   Google Scholar
• Miura T, Higashimurayama S, Kazuhiro O, et al. Compound containing a novel 4-alkoxypyrimidine structure and medicine containing same. US0322819; 2012
   Google Scholar
• Miura T, Higashimurayama S, Kazuhiro O, et al. Novel sulfonamide derivative and pharmaceutical product containing same. US0122906; 2012
   Google Scholar
• Fatheree PR, Hudson R, Murray R, et al. Dual-acting oxazole antihypertensive agents. US8372984; 2013
   Google Scholar
• Kim JH, Lee JH, Paik SH, et al. Fimasartan, a novel angiotensin II receptor antagonist. Arch Pharm Res 2012;35:1123-6
   PubMed Web of Science ®Google Scholar
• Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001;103:904-12
   PubMed Web of Science ®Google Scholar
• Cappelo B, Di Maio C, Iervolino M, Miro A. Improvement of solubility and stability of valsartan by hydroxypropyl-b-cyclodextrin. J Incl Phenom Macro 2006;54:289-94
   Google Scholar
• Tzoupis H, Leonis G, Megariotis G, et al. Dual inhibitors for aspartic proteases HIV-1 PR and renin: advancements in AIDS-hypertension-diabetes linkage via molecular dynamics, inhibition assays, and binding free energy calculations. J Med Chem 2012;55:5784-96
   PubMed Web of Science ®Google Scholar
• Fotakis C, Megariotis G, Christodouleas D, et al. Comparative study of the AT1 receptor prodrug antagonist candesartan cilexetil with other sartans on the interactions with membrane bilayers. Biochim Biophys Acta 2012;1818:3107-20
   PubMed Web of Science ®Google Scholar
• Ntountaniotis D, Mali G, Grdadolnik SG, et al. Thermal, dynamic and structural properties of drug AT1 antagonist olmesartan in lipid bilayers. Biochim Biophys Acta 2011;808:2995-3006
   Google Scholar
• Fotakis C, Christodouleas D, Zoumpoulakis P, et al. Comparative biophysical studies of sartan class drug molecules losartan and candesartan (CV-11974) with membrane bilayers. J Phys Chem B 2011;115:6180-92
   PubMed Web of Science ®Google Scholar
• Mavromoustakos T, Chatzigeorgiou P, Koukoulitsa C, et al. Partial interdigitation of lipid bilayers. Int J Quantum Chem 2011;6:1172-83
   Google Scholar
• Potamitis C, Chatzigeorgiou P, Siapi E, et al. Interactions of the AT1 antagonist valsartan with dipalmitoyl-phosphatidylcholine bilayers. Biochim Biophys Acta 2011;1808:1753-63
   Google Scholar
• Potamitis C, Zervou M, Katsiaras V, et al. Antihypertensive drug valsartan in solution and at the AT1 receptor: conformational analysis, dynamic NMR spectroscopy, in silico docking and molecular dynamics simulations. J Chem Inf Model 2009;49:726-39
   PubMed Web of Science ®Google Scholar
• Agelis D, Resvani A, Durdagi S, et al. The discovery of new potent non-peptide Angiotensin II AT1 receptor blockers: A concise synthesis, molecular docking studies and biological evaluation of N-substituted 5-butylimidazole derivatives. Eur J Med Chem 2012;55:358-74
   Google Scholar
• Politi A, Durdagi S, Moutevelis-Minakaki P, et al. Development of accurate binding affinity predictions of novel renin inhibitors through molecular docking studies. J Mole Graph & Model 2010;29:425-35
   PubMed Web of Science ®Google Scholar
• Politi A, Durdagi S, Moutevelis-Minakaki P, et al. Application of 3D QSAR CoMFA/CoMSIA and in silico docking studies on novel renin inhibitors against cardiovascular diseases. Euro J Med Chem 2009;44:3703-11
   PubMed Web of Science ®Google Scholar
• Agelis G, Roumelioti P, Resvani A, et al. An efficient synthesis of a rationally designed 1,5 disubstituted imidazole AT(1) Angiotensin II receptor antagonist: reorientation of imidazole pharmacophore groups in losartan reserves high receptor affinity and confirms docking studies. J Comput Aided Mole Des 2010;49:726-39
   Google Scholar